143 related articles for article (PubMed ID: 33743109)
41. Oral sodium bicarbonate protocol for high-dose methotrexate urine alkalinization: A pediatric experience.
Diachinsky M; Tran T; Jupp J; McKinnon K
J Oncol Pharm Pract; 2021 Jan; 27(1):119-127. PubMed ID: 32316877
[TBL] [Abstract][Full Text] [Related]
42. Pharmacodynamics of high-dose methotrexate in pediatric patients.
Aquerreta I; Aldaz A; Giráldez J; Sierrasesúmaga L
Ann Pharmacother; 2002 Sep; 36(9):1344-50. PubMed ID: 12196049
[TBL] [Abstract][Full Text] [Related]
43. The protective role of G protein-coupled estrogen receptor 1 (GPER-1) on methotrexate-induced nephrotoxicity in human renal epithelium cells.
Kurt AH; Bozkus F; Uremis N; Uremis MM
Ren Fail; 2016 Jun; 38(5):686-92. PubMed ID: 26981789
[TBL] [Abstract][Full Text] [Related]
44. Diabetes is a risk factor for high-dose methotrexate-associated AKI in lymphoma patients.
Wang Y; Wei L; Guan Y; Wang Q; Xie Q; Hao C
Ren Fail; 2020 Nov; 42(1):1111-1117. PubMed ID: 33164656
[TBL] [Abstract][Full Text] [Related]
45. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
[TBL] [Abstract][Full Text] [Related]
46. Fever as a risk factor causing delayed elimination of methotrexate in pediatric patients receiving high doses of cancer chemotherapy.
Kagawa Y; Mukohara R; Hori H; Kawasaki H; Komada Y; Kojima M
Cancer Chemother Pharmacol; 2004 Jul; 54(1):34-8. PubMed ID: 15024606
[TBL] [Abstract][Full Text] [Related]
47. The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue.
Zelcer S; Kellick M; Wexler LH; Gorlick R; Meyers PA
Pediatr Blood Cancer; 2008 Jun; 50(6):1176-80. PubMed ID: 18266225
[TBL] [Abstract][Full Text] [Related]
48. Effect of urine pH and flow on renal clearance of methotrexate.
Sand TE; Jacobsen S
Eur J Clin Pharmacol; 1981; 19(6):453-6. PubMed ID: 7250179
[TBL] [Abstract][Full Text] [Related]
49. Risk factors associated with high-dose methotrexate induced toxicities.
Li W; Mo J; Yang Z; Zhao Z; Mei S
Expert Opin Drug Metab Toxicol; 2024 Apr; 20(4):263-274. PubMed ID: 38501267
[TBL] [Abstract][Full Text] [Related]
50. [Correlation study of blood drug concentration and nephrotoxicity on high dose methotrexate therapy in suggestion of diagnosis and treatment of childhood acute lymphoblastic leukemia in the 4th revised edition].
Cheng DH; Lu H; Zou XQ
Zhonghua Er Ke Za Zhi; 2017 Oct; 55(10):771-774. PubMed ID: 29050116
[No Abstract] [Full Text] [Related]
51. Methotrexate on a 21-day cycle for low-risk gestational trophoblastic neoplasia.
Diaz J; Thomas MB; Paz-Pabon C; Hernandez E
J Reprod Med; 2012; 57(9-10):411-4. PubMed ID: 23091988
[TBL] [Abstract][Full Text] [Related]
52. Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.
Svahn T; Mellgren K; Harila-Saari A; Åsberg A; Kanerva J; Jónsson Ó; Vaitkeviciene G; Stamm Mikkelssen T; Schmiegelow K; Heldrup J
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27966809
[TBL] [Abstract][Full Text] [Related]
53. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.
Widemann BC; Balis FM; Kim A; Boron M; Jayaprakash N; Shalabi A; O'Brien M; Eby M; Cole DE; Murphy RF; Fox E; Ivy P; Adamson PC
J Clin Oncol; 2010 Sep; 28(25):3979-86. PubMed ID: 20679598
[TBL] [Abstract][Full Text] [Related]
54. [Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients].
Lin XB; Zhou NN; Li S; Cai QQ; Xia ZJ; Liao H; Gao Y; Huang HQ
Ai Zheng; 2008 Oct; 27(10):1100-5. PubMed ID: 18851792
[TBL] [Abstract][Full Text] [Related]
55. The impact of prehydration on the clearance and toxicity of high-dose methotrexate for pediatric patients.
Karremann M; Sauerbier J; Meier C; Vetter C; Schneider H; Buchholz B; Mildenberger S; Dürken M
Leuk Lymphoma; 2014 Dec; 55(12):2874-8. PubMed ID: 24576168
[TBL] [Abstract][Full Text] [Related]
56. Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma.
Pitman SW; Frei E
Cancer Treat Rep; 1977 Jul; 61(4):695-701. PubMed ID: 18282
[TBL] [Abstract][Full Text] [Related]
57. Toxicity associated with high-dose intravenous methotrexate for hematological malignancies.
Wight J; Ku M; Garwood M; Carradice D; Lasica M; Keamy L; Hawkes EA; Grigg A
Leuk Lymphoma; 2022 Oct; 63(10):2375-2382. PubMed ID: 35575146
[TBL] [Abstract][Full Text] [Related]
58. Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience.
Maestá I; Nitecki R; Horowitz NS; Goldstein DP; de Freitas Segalla Moreira M; Elias KM; Berkowitz RS
Gynecol Oncol; 2018 Jan; 148(1):161-167. PubMed ID: 29092742
[TBL] [Abstract][Full Text] [Related]
59. Evaluating performance of a decision support system to improve methotrexate pharmacotherapy in children and young adults with cancer.
Dombrowsky E; Jayaraman B; Narayan M; Barrett JS
Ther Drug Monit; 2011 Feb; 33(1):99-107. PubMed ID: 21192315
[TBL] [Abstract][Full Text] [Related]
60. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
